The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.

abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

journal_title：Prostate cancer and prostatic diseases

authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...

journal_title：Prostate cancer and prostatic diseases

authors： Mano R,Eastham J,Yossepowitch O

更新日期：2016-12-01 00:00:00

abstract：:To describe practice patterns of primary care physicians (PCPs) for the diagnosis, treatment and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we surveyed 556 PCPs in Boston, Chicago, and Los Angeles (RR=52%). Only 62% reported ever seeing a patient like the one described in the vignette. I...

journal_title：Prostate cancer and prostatic diseases

authors： Calhoun EA,Clemens JQ,Litwin MS,Walker-Corkery E,Markossian T,Kusek JW,McNaughton-Collins M

更新日期：2009-01-01 00:00:00

abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

journal_title：Prostate cancer and prostatic diseases

authors： Neuhausen SL

更新日期：2000-12-01 00:00:00

abstract：PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

journal_title：Prostate cancer and prostatic diseases

authors： Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

journal_title：Prostate cancer and prostatic diseases

authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

journal_title：Prostate cancer and prostatic diseases

authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

更新日期：2019-09-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimen...

journal_title：Prostate cancer and prostatic diseases

authors： Walsh K,Sriprasad S,Hopster D,Codd J,Mulvin D

更新日期：2002-01-01 00:00:00

abstract：:Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...

journal_title：Prostate cancer and prostatic diseases

authors： Daja MM,Niu X,Zhao Z,Brown JM,Russell PJ

更新日期：2003-01-01 00:00:00

abstract：:Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...

journal_title：Prostate cancer and prostatic diseases

authors： Yaturu S,DjeDjos S,Alferos G,Deprisco C

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

journal_title：Prostate cancer and prostatic diseases

authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

更新日期：2015-03-01 00:00:00

abstract：:The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

journal_title：Prostate cancer and prostatic diseases

authors： Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Emerging evidence suggests that diabetes may increase the risk of cancers. However, available evidence on prostate cancer is conflicting. We therefore examined the association between Type 2 diabetes and risk of prostate cancer by conducting a detailed meta-analysis of all studies published regarding this su...

journal_title：Prostate cancer and prostatic diseases

authors： Bansal D,Bhansali A,Kapil G,Undela K,Tiwari P

更新日期：2013-06-01 00:00:00

abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

journal_title：Prostate cancer and prostatic diseases

authors： Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

journal_title：Prostate cancer and prostatic diseases

authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

更新日期：2020-09-03 00:00:00

abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Rossi PJ,Jani AB,Master V

更新日期：2007-01-01 00:00:00

abstract：:Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expect...

journal_title：Prostate cancer and prostatic diseases

authors： Gómez-Sancha F

更新日期：1999-12-01 00:00:00

abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

journal_title：Prostate cancer and prostatic diseases

authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

journal_title：Prostate cancer and prostatic diseases

authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

更新日期：2020-12-01 00:00:00

abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

journal_title：Prostate cancer and prostatic diseases

authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

更新日期：2018-09-01 00:00:00

abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

journal_title：Prostate cancer and prostatic diseases

authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

更新日期：2000-12-01 00:00:00

abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

journal_title：Prostate cancer and prostatic diseases

authors： Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

更新日期：2012-03-01 00:00:00

abstract：:Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treat...

journal_title：Prostate cancer and prostatic diseases

authors： Tomic R,Ljungberg B

更新日期：1999-07-01 00:00:00

abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

journal_title：Prostate cancer and prostatic diseases

authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

更新日期：2018-09-01 00:00:00

abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-12-01 00:00:00

abstract：:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...

journal_title：Prostate cancer and prostatic diseases

authors： Zhou T,Xu C,He M,Sun Y

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...

journal_title：Prostate cancer and prostatic diseases

authors： Nafie S,Mellon JK,Dormer JP,Khan MA

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...

journal_title：Prostate cancer and prostatic diseases

authors： Li Q,Lan L,Klaassen Z,Shah SR,Moses KA,Terris MK

更新日期：2013-12-01 00:00:00

abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...

journal_title：Prostate cancer and prostatic diseases

authors： Sadetsky N,Elkin EP,Latini DM,DuChane J,Carroll PR,CaPSURE Investigators.

更新日期：2008-01-01 00:00:00

abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...

journal_title：Prostate cancer and prostatic diseases

authors： Sedelaar JP,De La Rosette JJ,Beerlage HP,Wijkstra H,Debruyne FM,Aarnink RG

更新日期：1999-12-01 00:00:00